Baseline and clinical characteristics of children with IVR and LP
| Characteristics | IVR group | LP group | T | P value |
| No of eyes/children | 28/17 | 37/20 | / | / |
| Sex (male/female) | 8/9 | 10/10 | / | 0.86* |
| BGA, weeks | 30.0±2.6 | 29.2±2.5 | −0.89 | 0.38 |
| BW, g | 1246±377 | 1250±323 | 0.04 | 0.97 |
| CGA, weeks | 37.4±1.6 | 36.9±2.0 | −0.74 | 0.46 |
| Age of OCTA examination, years | 5.4±1.1 | 6.3±1.8 | 1.85 | 0.07 |
| Way of birth (NB/CS) | 6/11 | 12/8 | / | 0.13* |
| Central foveal VLD | 13.82±2.99 | 15.64±2.71 | 2.56 | 0.01 |
| Parafoveal VLD | 21.71±2.37 | 22.51±1.66 | 1.59 | 0.12 |
| Foveal VLD | 20.82±2.35 | 21.73±1.73 | 1.80 | 0.07 |
| FAZ area (mm2) | 0.13±0.09 | 0.09±0.07 | −2.01 | 0.048 |
| FAZ MI | 0.62±0.23 | 0.51±0.28 | −1.56 | 0.12 |
| Central foveal PD | 0.25±0.05 | 0.28±0.05 | 2.82 | 0.006 |
| Parafoveal PD | 0.39±0.04 | 0.41±0.03 | 1.72 | 0.09 |
| Foveal PD | 0.38±0.04 | 0.39±0.03 | 1.97 | 0.054 |
| CFT (μm) | 200.7±16.7 | 220.9±22.7 | 5.83 | <0.01 |
| BCVA (Log MAR) | 0.2±0.1 | 0.1±0.1 | −2.67 | 0.01 |
| SER (D) | 0.31±2.4 | 0.13±2.1 | −0.32 | 0.75 |
*X2 test; The remaining indices are the t-test.
BCVA, best-corrected visual acuity; BGA, born in gestational age; BW, birth weight; CFT, central foveal thickness; CGA, corrected gestational age at treatment; CS, caesarean section; FAZ, foveal avascular zone; IVR, intravitreal injection of ranibizumab; LogMAR, logarithm of the minimal angle of resolution; LP, laser photocoagulation; MI, Morphological Index; NB, natural birth; OCTA, optical coherence tomography angiography; PD, perfusion density; SER, spherical equivalent refraction; VLD, vessel length density.